Search

Your search keyword '"Liu, Wei Jing"' showing total 254 results
Start Over Author "Liu, Wei Jing"
254 results on '"Liu, Wei Jing"'

4. Integrated Network Pharmacology Analysis and Experimental Validation to Elucidate the Mechanism of Acteoside in Treating Diabetic Kidney Disease

Author

Zhang, Shu Jiao, primary, Zhang, Yi Fei, additional, Bai, Xue Hui, additional, Zhou, Meng Qi, additional, Zhang, Ze Yu, additional, Zhang, Shuai Xing, additional, Cao, Zi Jing, additional, Wang, Lin, additional, Ding, Shao Wei, additional, Zheng, Hui Juan, additional, Liu, Yu Ning, additional, Yu, Guo Yong, additional, and Liu, Wei Jing, additional

Published
2024
Full Text
View/download PDF

8. Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy

Author

Yu, Borui, primary, Zhou, Mengqi, additional, Dong, Zhaocheng, additional, Zheng, Huijuan, additional, Zhao, Yuxue, additional, Zhou, Jingwei, additional, Zhang, Chao, additional, Wei, Fudong, additional, Yu, Guoyong, additional, Liu, Wei Jing, additional, Liu, Hongfang, additional, and Wang, Yaoxian, additional

Published
2023
Full Text
View/download PDF

16. Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis

Author

Xue, Cheng Yuan, primary, Zhou, Meng Qi, additional, Zheng, Qi Yan, additional, Zhang, Jin Hui, additional, Cheng, Wei Ting, additional, Bai, Xue Hui, additional, Zhou, Fen, additional, Wu, Ai Ming, additional, Nie, Bo, additional, Liu, Wei Jing, additional, and Lou, Li Xia, additional

Published
2022
Full Text
View/download PDF

17. Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer

Author

Liu, Kun, primary, Chen, Yu, additional, Shi, Xiao-Bao, additional, Xing, Zi-Hao, additional, He, Zheng-Jie, additional, Wang, Sheng-Te, additional, Li, Yan-Chi, additional, Liu, Wei-Jing, additional, Zhang, Peng-Wei, additional, Yu, Ze-Zhong, additional, Mo, Xue-Mei, additional, Shi, Xing-Yuan, additional, Chen, Zhe-Sheng, additional, and Shi, Zhi, additional

Published
2022
Full Text
View/download PDF

25. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Author

Luo, Qian, Wei, Ruojun, Cai, Yuzi, Zhao, Qihan, Liu, Yuning, and Liu, Wei Jing

Subjects
General Medicine
Abstract

ObjectiveTo evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD).DesignA network meta-analysis.Data SourcesPubMed, Embase, Cochrane Library, and Web of Science databases from their inception until September 1, 2021.Eligibility Criteria for Selecting StudiesRandomized controlled trials (RCTs) comparing the effects of four different drugs in patients with NAFLD were included. All superiority, non-inferiority, phase II and III, non-blinded, single-blinded, and double-blinded trials were included. Interventions of interest included vitamin E (α-tocopherol and δ-tocotrienol), pioglitazone, three kinds of GLP-1 receptor agonists (liraglutide, semaglutide, and dulaglutide), four SGLT2 inhibitors (dapagliflozin, empagliflozin, ipragliflozin, and tofogliflozin), and comparisons of these different drugs, and placebos.Main Outcome MeasuresThe outcome measures included changes in non-invasive tests [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), controlled attenuation parameter (CAP), enhanced liver fibrosis (ELF) score, liver fat content (LFC), and keratin-18 (K-18)] and invasive tests [fibrosis score and resolution of non-alcoholic steatohepatitis (NASH)].ResultsTwenty-seven trials including 3,416 patients were eligible for inclusion in the study. Results refer to vitamin E, pioglitazone, GLP-1 receptor agonists, and SGLT2 inhibitors. First, placebos were used as a reference. δ-Tocotrienol was superior to placebo in decreasing the GGT level. Semaglutide, ipragliflozin, and pioglitazone induced a significantly higher decrease in the ALT level than a placebo. Semaglutide, pioglitazone, and dapagliflozin were superior to placebo in decreasing the AST level. Tofogliflozin and pioglitazone induced a significantly higher decrease in the K-18 level than a placebo. Liraglutide was superior to placebo in decreasing CAP. Liraglutide, pioglitazone, and vitamin E induced a significantly higher increase in resolution of NASH than a placebo. As for pairwise comparisons, semaglutide and pioglitazone were superior to liraglutide in decreasing the ALT level. Semaglutide induced a significantly higher decrease in the ALT level than dulaglutide. Semaglutide was obviously superior to empagliflozin, liraglutide, dulaglutide, and tofogliflozin in decreasing the AST level. Pioglitazone induced a significantly higher decrease in the GGT level than ipragliflozin. δ-Tocotrienol was superior to liraglutide in decreasing the GGT level. Tofogliflozin and pioglitazone induced a significantly higher decrease in the K-18 level than dulaglutide. Pioglitazone was superior to vitamin E in increasing the resolution of NASH. Furthermore, liraglutide treatment had the highest SUCRA ranking in decreasing CAP and ELF scores and increasing the resolution of NASH. Pioglitazone treatment had the highest SUCRA ranking in decreasing LFC and fibrosis scores. Tofogliflozin treatment had the highest SUCRA ranking in decreasing K-18, while dapagliflozin treatment had the highest SUCRA ranking in decreasing the GGT level. Semaglutide treatment had the highest SUCRA ranking in decreasing the levels of ALT and AST.ConclusionThe network meta-analysis provided evidence for the efficacy of vitamin E, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists in treating patients with NAFLD. To find the best guide-level drugs, it is necessary to include more RCTs with these off-label drugs, so that patients and clinicians can make optimal decisions together.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero, identifier: CRD42021283129.

Published
2022

32. AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer

Author

Liu, Kun, primary, Li, Yan-Chi, additional, Chen, Yu, additional, Shi, Xiao-Bao, additional, Xing, Zi-Hao, additional, He, Zheng-Jie, additional, Wang, Sheng-Te, additional, Liu, Wei-Jing, additional, Zhang, Peng-Wei, additional, Yu, Ze-Zhong, additional, Mo, Xue-Mei, additional, Chen, Mei-Wan, additional, Chen, Zhe-Sheng, additional, and Shi, Zhi, additional

Published
2021
Full Text
View/download PDF

37. Efficacy of Intermittent or Continuous Very Low-Energy Diets in Overweight and Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analyses

Author

Huang, Yi Shan, Zheng, Qiyan, Yang, Huisheng, Fu, Xinwen, Zhang, Xueqin, Xia, Chenhui, Zhu, Zebing, Liu, Yu Ning, and Liu, Wei Jing

Subjects
Article Subject
Abstract

Objective. This study is aimed at investigating the efficacy of a very low-energy diet (VLED) in overweight and obese individuals with type 2 diabetes mellitus (T2DM). Methods. We thoroughly searched eight electronic resource databases of controlled studies concerning the efficacy and acceptability of intermittent or continuous VLEDs in patients with T2DM compared with other energy restriction interventions. Results. Eighteen studies (11 randomized and seven nonrandomized controlled trials) with 911 participants were included. The meta-analyses showed that compared with a low-energy diet (LED) and mild energy restriction (MER), VLED is superior in the reduction of body weight (mean difference (MD) MDLED=−2.77, 95% confidence interval (CI) CILED=−4.81 to−0.72, PLED=0.008; MDMER=−6.72, 95%CIMER=−10.05 to−3.39, PMER

Published
2020
Full Text
View/download PDF

38. Modulation of the Gut Microbiota by Shen-Yan-Fang-Shuai Formula Improves Obesity Induced by High-Fat Diets

Author

Wang, Zhen, primary, Lu, Junfeng, additional, Zhou, Jingwei, additional, Sun, Weiwei, additional, Qiu, Yang, additional, Chen, Weihong, additional, Gao, Yabin, additional, Yang, Ruibing, additional, Ai, Sinan, additional, Liu, Zhongjie, additional, Guo, Yingbo, additional, Liu, Wei Jing, additional, Wang, Yaoxian, additional, and Peng, Liang, additional

Published
2020
Full Text
View/download PDF

46. Accelerated Kidney Aging in Diabetes Mellitus

Author

Guo, Jing, primary, Zheng, Hui Juan, additional, Zhang, Wenting, additional, Lou, Wenjiao, additional, Xia, Chenhui, additional, Han, Xue Ting, additional, Huang, Wei Jun, additional, Zhang, Fan, additional, Wang, Yaoxian, additional, and Liu, Wei Jing, additional

Published
2020
Full Text
View/download PDF

47. Si-Miao-Yong-An (SMYA) Decoction May Protect the Renal Function Through Regulating the Autophagy-Mediated Degradation of Ubiquitinated Protein in an Atherosclerosis Model

Author

Zhu, Ze-Bing, primary, Song, Ke, additional, Huang, Wei-Jun, additional, Li, Hui, additional, Yang, Hui, additional, Bai, Yun-Qi, additional, Guo, Ke-Ting, additional, Yang, Rui-Bing, additional, Lou, Wen-Jiao, additional, Xia, Chen-Hui, additional, Nie, Bo, additional, and Liu, Wei-Jing, additional

Published
2020
Full Text
View/download PDF

50. Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials

Author

Zheng, Hui Juan, primary, Guo, Jing, additional, Wang, Qiuhong, additional, Wang, Liansheng, additional, Wang, Yahui, additional, Zhang, Fan, additional, Huang, Wei-Jun, additional, Zhang, Wenting, additional, Liu, Wei Jing, additional, and Wang, Yaoxian, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results